Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting
Table 3
SVR 12 rates in patients receiving LDV/SOF by population subgroup.
Response
SVR 12 Rate
Univariate Analysis p-value
Multivariate Analysis p-value
Overall
78/87 (89.7)
Age group
1.000
NA
< 65
49/55 (89.1)
≥ 65
29/32 (90.6)
Sex
1.000
NA
Male
44/51 (86.3)
Female
34/36 (94.4)
BMI (Kg/m2)
0.304
NA
< 30
45/52 (86.5)
≥ 30
33/35 (94.3)
HCV Genotype
0.009
0.983
1a
45/52 (86.5)
1b
28/28 (100)
2
3/4 (75.0)
3
2/2 (100)
4
0/1 (0)
HCV RNA (IU/mL)
1.000
NA
< 800,000
23/26 (88.5)
≥ 800,000
55/61 (90.2)
Prior treatment
0.682
NA
Naïve
62/70 (88.6)
Experienced
16/17 (94.1)
Comorbidities
Diabetes
21/25 (84.0)
0.272
NA
Hypertension
33/37 (89.2)
1.000
NA
CAD
9/9 (100)
0.589
NA
Kidney disease
7/8 (87.5)
1.000
NA
Chronic anemia
2/2 (100)
1.000
NA
HIV Seropositive
18/21 (85.7)
0.681
NA
MELD Score
0.154
NA
< 10
48/51 (94.1)
≥ 10
30/36 (83.3)
ALT (IU/L)
0.678
NA
< 40
17/18 (94.4)
≥ 40
61/69 (88.4)
Data presented as number/total number (percent). Only variables with the p-value < 0.05 in univariate analysis were assessed. BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; APRI, AST-to-platelet ratio index; MELD, model for end-stage liver disease; and ALT, alanine transaminase
